American Headache Society Annual Scientific Meeting

Videos

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.

Matthew Robbins, MD: Headaches Associated With COVID-19

The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.

Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment

Alicia Bigica is the Associate Editorial Director for 

. Prior to joining MJH Life Sciences in 2019, she helped launch leading resources for medical news in the neurology and dermatology specialties. Follow her on Twitter 

Articles

Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic. 

Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine

Matt Hoffman, Senior Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments podcast, as well as Second Opinion on Medical World News. Follow him on Twitter 

The head of Neurology Medical at Lundbeck Seattle Biopharmaceuticals offers perspective on the findings and what impact eptinezumab may have on migraine care.

Roger Cady, MD: Rapid Effect of Eptinezumab on Migraine

Treatment with galcanezumab (Emgality; Eli Lilly) was associated with improvements in total pain burden for patients with both chronic and episodic migraine compared to placebo groups.

Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.

Matthew Robbins, MD: Residency During COVID-19

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.

Chia-Chun Chiang, MD: Collecting Real-World Data Following FDA Approvals

The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.

Long-Term Safety Study Confirms Efficacy of ADAM Zolmitriptan in Acute Migraine

The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.

Chia-Chun Chiang, MD: Variations in FDA Approved Migraine Medications

, has been with the team since October 2019. Follow him on Twitter 

In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.